Respiratory Syncytial Virus, Human
"Respiratory Syncytial Virus, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of PNEUMOVIRUS and an important cause of lower respiratory disease in infants and young children. It frequently presents with bronchitis and bronchopneumonia and is further characterized by fever, cough, dyspnea, wheezing, and pallor.
| Descriptor ID |
D018113
|
| MeSH Number(s) |
B04.820.455.600.670.600.750.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus, Human".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus, Human".
This graph shows the total number of publications written about "Respiratory Syncytial Virus, Human" by people in this website by year, and whether "Respiratory Syncytial Virus, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus, Human" by people in Profiles.
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
-
Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. Vaccine. 2023 08 14; 41(36):5265-5270.
-
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
-
Epidemiology of Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children One Year of Age and Older-Washington State, 2011/2012-2015/2016. J Infect Dis. 2021 01 04; 223(1):147-156.
-
Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020 09 14; 222(8):1298-1310.
-
Cost of Hospitalization Associated With Respiratory Syncytial Virus Infection Versus Influenza Infection in Hospitalized Older Adults. J Infect Dis. 2020 08 17; 222(6):962-966.
-
MUC5AC Levels Associated With Respiratory Syncytial Virus Disease Severity. Clin Infect Dis. 2018 10 15; 67(9):1441-1444.
-
Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma. J Allergy Clin Immunol. 2017 01; 139(1):66-71.e3.
-
Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLoS Pathog. 2015 Jan; 11(1):e1004591.
-
Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLoS Med. 2015 Jan; 12(1):e1001776.